ASTRAZENECA, the pha­r­maceutical giant which virtually became a household name during the Covid-19 pandemic, has admitted that its Covishield vaccine could cause rare side effects, including blood clots and low platelet count.

The pharma giant is being sued in a class action over claims that its vaccine, developed with the University of Oxford, caused death and serious injury in dozens of cases.

“It is admitted that the AZ vaccine can, in very rare cases, cause TTS (Thrombosis with Thrombocytopenia Syndrome). The causal mechanism is not known,” the company said in court documents, The Telegraph reported.

Covishield was developed by the British-Swedish company in collaboration with Oxford University, and produced by the Serum Institute of India. It was widely administered in over 150 countries.

Some studies conducted during the pandemic found the vaccine was 60 to 80 per cent effective in protecting against the novel coronavirus, according to The Independent.

But one of the complainants alleged that the vaccine caused him a permanent brain injury after he developed a blood clot, preventing him from working.

While the company has contested these claims, the court submission marks the first time it has admitted that the vaccine can cause side-effects that are characterised by blood clots and a low blood platelet count in humans.

“Further, TTS can also occur in the absence of the AZ vaccine (or any vaccine). Causation in any individual case will be a matter for expert evidence,” it added.

The admission by AstraZeneca runs counter to the company’s insistence in 2023 that it would “not accept that TTS is caused by the vaccine at a generic level”, according to The Independent.

Scientists first identified a link between the vaccine and a new illness called vaccine-induced immune thrombocytopenia and thrombosis (VITT) in March 2021.

The UK government has indemnified Astra­Zeneca against any legal action but has so far refused to intervene, according to The Telegraph.

According to the Council for International Organisat­ions of Medical Sciences, “very rare” side effects are those reported in less than 1 in 10,000 cases.

Published in Dawn, May 1st, 2024

Opinion

Editorial

Economic plan
Updated 02 Jan, 2025

Economic plan

Absence of policy reforms allows the bureaucracy a lot of space to wriggle out of responsibility.
On life support
02 Jan, 2025

On life support

PAKISTAN stands at a precarious crossroads as we embark on a new year. Pildat’s Quality of Democracy report has...
Harsh sentence
02 Jan, 2025

Harsh sentence

USING lawfare to swiftly get rid of political opponents makes a mockery of the legal system, especially when ...
Looking ahead
Updated 01 Jan, 2025

Looking ahead

The dawn of 2025 brings with it hope of a more constructive path to much-needed stability.
On the front lines
Updated 01 Jan, 2025

On the front lines

THE human cost of terrorism in 2024 was staggering. The ISPR reports 383 officers and soldiers embraced martyrdom...
Avoiding reform
01 Jan, 2025

Avoiding reform

PAKISTAN’S economic growth significantly slowed down to a modest 0.92pc during the first quarter of the present...